MUC1 and non-small cell squamous lung carcinoma: PEM is a newly developed folate antagonist capable of inhibiting multiple folate-metabolizing enzymes, and it has been approved as a therapeutic drug for non-squamous non-small-cell lung cancer and mesothelioma by the FDA [12,13].